{"id":36874,"date":"2015-09-18T15:23:48","date_gmt":"2015-09-18T19:23:48","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=36874"},"modified":"2015-09-18T15:23:48","modified_gmt":"2015-09-18T19:23:48","slug":"pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874","title":{"rendered":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ?"},"content":{"rendered":"<p style=\"text-align: justify;\">Shares of <strong>Vascular Biogenics Ltd. (NASDAQ:VBLT)<\/strong> surged by more than 29% after the company announced that they will be presenting their data at the European society of Medical Oncology Conference. VBLT opened at $5.40 and soon went on to hit the intraday high of $7.36 for a massive 29 percent in gains. The company\u2019s ticket to fame is the proprietary drug VB-111, a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. As per the press release, the Company will be presenting its <strong>Phase 2 data on VB-111 in combination with bevacizumab (Avastin)<\/strong> at the ESMO European Cancer Congress 2015 in Vienna, Austria. It seems investors are expecting positive data from the trial as more than 1.7M shares have exchanged hands today. Nevertheless, only time will tell if the <strong>today\u2019s hype is worth all the attention.<\/strong><\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/VBLT.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter size-full wp-image-36875\" src=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/VBLT.png\" alt=\"VBLT\" width=\"700\" height=\"530\" srcset=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/VBLT.png 700w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/VBLT-300x227.png 300w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/VBLT-73x55.png 73w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">Similar to Vascular Biogenics Ltd. (NASDAQ: VBLT), another small cap biotech company that caught our attention today is <strong>Pharmacyte Biotech Inc (OTCMKTS:PMCB)<\/strong>. PMCB is developing treatments for <strong>cancer and diabetes based upon their unique<\/strong>, proprietary and patented cellulose-based live cell encapsulation technology known as <strong>Cell-in-a-Box\u00ae<\/strong>. \u00a0Early studies have shown the Cell-in-a-Box technology can be used to encapsulate a human cell line genetically engineered to produce, store, and secrete insulin, thereby representing a potential cure for Diabetes through a true \u201cbio-artificial\u201d pancreas. <strong>PharmaCyte (PMCB) has been working feverishly<\/strong> over the past year to position itself to move into FDA trials and work towards its first FDA Approval as a therapy for Pancreatic Cancer. It appears that with it\u2019s a <strong>remarkable technology<\/strong>, PMCB could be getting closer to getting into an <strong>FDA clinical trial than ever<\/strong>. Rather than the standard Phase 1 clinical trial, PharmaCyte (PMBC) plans to move directly to a Phase 2b trial as the data from the original treatment on humans is expected to suffice in place of Phase 1-2. The stock only trades in the <strong>$.09 to $.10 range<\/strong>, but has the unfathomable upside potential of representing possible therapies for many kinds of cancer and diabetes. A quick review of the release string of press releases should lead you to the conclusion this company is on the <strong>verge of major breakthroughs,<\/strong> which is likely to lead to higher prices.<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/PMCB.png\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-36876\" src=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/PMCB.png\" alt=\"PMCB\" width=\"700\" height=\"530\" srcset=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/PMCB.png 700w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/PMCB-300x227.png 300w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/09\/PMCB-73x55.png 73w\" sizes=\"(max-width: 700px) 100vw, 700px\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) surged by more than 29% after the company announced that they will be presenting their data at the European [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":41703,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[11749,11643,11642,11751,11748,11750],"stock_ticker":[],"class_list":["post-36874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-nasdaqvblt","tag-otcmktspmcb","tag-pharmacyte-biotech-inc","tag-pmcb","tag-vascular-biogenics-ltd","tag-vblt","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ? - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ? - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) surged by more than 29% after the company announced that they will be presenting their data at the European [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-09-18T19:23:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"770\" \/>\n\t<meta property=\"og:image:height\" content=\"433\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ?\",\"datePublished\":\"2015-09-18T19:23:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874\"},\"wordCount\":388,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg\",\"keywords\":[\"NASDAQ:VBLT\",\"OTCMKTS:PMCB\",\"Pharmacyte Biotech Inc\",\"PMCB\",\"Vascular Biogenics Ltd\",\"VBLT\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874\",\"name\":\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ? - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg\",\"datePublished\":\"2015-09-18T19:23:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg\",\"width\":770,\"height\":433},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ? - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874","og_locale":"en_US","og_type":"article","og_title":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ? - Wall Street PR","og_description":"Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) surged by more than 29% after the company announced that they will be presenting their data at the European [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-09-18T19:23:48+00:00","og_image":[{"width":770,"height":433,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ?","datePublished":"2015-09-18T19:23:48+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874"},"wordCount":388,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg","keywords":["NASDAQ:VBLT","OTCMKTS:PMCB","Pharmacyte Biotech Inc","PMCB","Vascular Biogenics Ltd","VBLT"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874","url":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874","name":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ? - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg","datePublished":"2015-09-18T19:23:48+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet9.jpg","width":770,"height":433},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pharmacyte-biotech-inc-otcmktspmcb-on-path-to-be-the-next-vascular-biogenics-ltd-nasdaqvblt-36874#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Pharmacyte Biotech Inc (OTCMKTS:PMCB) on path to be the next Vascular Biogenics Ltd. (NASDAQ:VBLT) ?"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=36874"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36874\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/41703"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=36874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=36874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=36874"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=36874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}